SeaX Invests in Eigen to Tackle Cancer with Game-Changing Priming Therapies
SeaX Ventures, a leading deep-tech venture capital fund known for its investments in groundbreaking technologies, has announced its investment in Eigen Therapeutics, a biotech innovator revolutionizing cancer treatment with its groundbreaking “priming therapy” platform. This investment fuels Eigen’s mission to unlock the full potential of targeted cancer therapies, addressing inefficiencies that plague current approaches.
Cracking the code on targeted therapies:
Current cancer treatments like antibody-drug conjugates (ADCs) hold immense promise, but their effectiveness is often hampered by limitations. Tumors are a heterogeneous beast, with variable antigen expression that can render therapies off-target and ineffective. Eigen tackles this head-on with its novel priming therapy platform, strategically preparing cancer cells to maximize the potency of targeted treatments.
Priming for Precision:
Eigen’s proprietary platform is a game-changer in the discovery and development of priming agents. Their integrated system leverages the power of AI, high-throughput robotic screening, and a custom compound library to identify and validate the most effective agents with unprecedented speed and precision. This positions Eigen at the forefront of priming therapy innovation, poised to unlock a new era of cancer treatment.
Investing in visionary leadership:
SeaX Ventures, known for its discerning eye for transformative technologies, recognizes the immense potential of Eigen’s approach. “Eigen’s priming therapies are a paradigm shift,” says Dr. Kid Parchariyanon, Founder and Managing Partner at SeaX Ventures. “Their unique platform has the power to dramatically enhance targeted therapies, reducing side effects and improving patient outcomes. We’re thrilled to partner with this visionary team and accelerate their quest to redefine cancer treatment.”
Shared vision, bold impact:
“Partnering with SeaX Ventures is a watershed moment,” says Transon Nguyen, co-founder and CEO of Eigen Therapeutics. “Their deep understanding of disruptive technologies aligns perfectly with our mission. This investment fuels our journey to translate priming therapies into tangible hope for cancer patients everywhere.”
Joining forces for a healthier future:
This landmark investment is fueled not only by SeaX Ventures, but also esteemed partners like First Round Capital and Builders VC. It signifies a collective commitment to push the boundaries of cancer treatment and empower Eigen to realize its transformative potential. With this powerful backing, Eigen is poised to prime the future of cancer treatment, offering a brighter outlook for millions of patients worldwide.
About SeaX Ventures
SeaX Ventures, also known as Southeast Asia Exponential Ventures, is a venture capital fund investing globally in early-stage companies poised to disrupt industries with “exponential” technologies. Partnering with our LPs, which include some of the largest corporations in Asia, we aim to accelerate the growth of our portfolio companies.
